What is the drug being tested?

Hydroxychloroquine is commonly used to treat malaria and rheumatological conditions and its side effects are well-known. The doses used in this trial are at the lower end of the range of normal treatment doses prescribed for the conditions they are licensed for, so side effects may be less likely to occur.

This is a double-blind trial meaning neither you nor the trial doctor will know which treatment you have been assigned to.

Discover more about the NIHR Cambridge BRC

Contact us by phone, email or web for more information.

Events Calendar

Listing relevant events and training sessions for researchers and members of the public.